Crovalimab is a novel, engineered anti-complement C5 monoclonal antibody developed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Marketed under the brand name PiaSky®, it is distinguished by its unique pH-dependent, recycling mechanism. This design allows for sustained complement inhibition with a significantly longer half-life, enabling convenient subcutaneous administration every four weeks, unlike the standard intravenous regimens of other C5 inhibitors. It provides an effective therapeutic option for PNH patients, including those who may have experienced breakthrough hemolysis on other C5 therapies.